OBJECTIVE To compare the clinicopathologic features and survival in the four breast cancer subtypes defined by immunohistochemistry (IHC) expression of estrogen receptor (ER) or progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2): ER/PR+, Her2+; ER/PR+, Her2-; ER/PR-, Her2+; and ER/PR-, Her2-. METHODS A 7-year retrospective study of 1134 invasive breast cancer subje...

In women with metastatic breast cancer (MBC), introduction of the anti-HER2 (human epidermal growth factor receptor-2) directed therapies including trastuzumab, pertuzumab, lapatinib, and/or trastuzumab-DM1 has markedly improved overall survival. However, not all cases of HER2-positive breast tumours derive similar benefit from HER2-directed therapy, and a significant number of patients experie...

background: triple negative breast cancer (tnbc) is reported to be associated with a high risk of recurrence, poor overall survival (os), and disease-free survival (dfs) rates. this study evaluated the clincopathological features and survival of non-metastatic tnbc women in the capital of iran compared with other areas of the world. methods: in a retrospective study, 119 women with tnbc based o...

Until recently, despite its heterogenous biology, metastatic triple negative breast cancer (TNBC) was treated as a single entity, with successive lines of palliative chemotherapy being the only systemic option. Significant gene expression studies have demonstrated diversity TNBC, but effective differential targeting four main (Basal-like 1 and 2, mesenchymal luminal androgen receptor) molecular...

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family having tyrosine kinase activity. Dimerization of the receptor results in the autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptors and initiates a variety of signaling pathways leading to cell proliferation and tumorigenesis. Amplification or overexpressio...

in this study, we synthesized herceptin conjugated magnetic nanoparticles (hmns) as an alternative probe to discover the levels of her2 (human epidermal growth factor receptor-2) in the surface of cells. these nanoparticles can be used by magnetic resonance imaging (mri) (non-invasive methods) for screening the patients with her2 positive or negative tumors. dextran coated iron oxide nanopartic...

The clinical implications of HER-2/neu (HER2) expression in ductal carcinoma in situ (DCIS) lesions have yet to be clearly elucidated; this despite the more frequent expression of HER2 in high-grade DCIS lesions compared with invasive cancers. We hypothesized that HER2 overexpression in DCIS is associated with more rapid progression to invasive disease. Immunohistochemical staining for estrogen...

The article presents a clinical case illustrating the effectiveness of abemaciclib in combination with anastrozole metastatic estrogen receptor-positive HER2/neu-negative breast cancer (BC). CDK4/6 inhibitors have changed paradigm treatment patients hormone-positive HER2 BC. Thanks to ability palbociclib, ribociclib and delay overcome resistance endocrine therapy, not only newly diagnosed disea...

BACKGROUND In 2010, Surveillance, Epidemiology, and End Results (SEER) registries began collecting human epidermal growth factor 2 (HER2) receptor status for breast cancer cases. METHODS Breast cancer subtypes defined by joint hormone receptor (HR; estrogen receptor [ER] and progesterone receptor [PR]) and HER2 status were assessed across the 28% of the US population that is covered by SEER r...